SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is actively trending, fueled by its community's strong promotion of cannabis culture and its potential to disrupt traditional industries. As a Solana-based token, it's frequently touted as 'Bitcoin but way higher,' with widespread discussion on its role in advancing natural medicine and environmental sustainability through hemp, driving significant community engagement.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is experiencing significant buzz as the market anticipates an imminent Executive Order, widely expected to reschedule marijuana to a Schedule III drug. Community sentiment is sharply split, with many predicting a massive short squeeze and a surge of institutional investment from potential 280E tax relief, while others caution about a possible "sell the news" reaction or a "rug pull" as the event unfolds.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending following a recent address by Donald Trump, which has ignited intense debate among investors. Supporters hailed the speech as a powerful assertion of his administration's accomplishments and future plans, while critics widely dismissed it as disjointed and containing misinformation. Community discussion is highly polarized, focusing on economic policies, legal challenges, and the potential implications of the political landscape on the stock.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending after reporting blockbuster earnings and providing incredibly strong guidance, largely driven by surging demand for its high-bandwidth memory (HBM) essential for AI. The community is buzzing with optimism, seeing this as a powerful affirmation of the AI growth story and hoping it can help stabilize the broader tech market. Investors are particularly focused on the company's expanding gross margins and sold-out HBM supply into 2026.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

The AdvisorShares Pure US Cannabis ETF (MSOS) is trending amid intense speculation that an executive order reclassifying cannabis to Schedule III is imminent, with reports suggesting an upcoming signing event with industry executives. This potential reform is driving significant community excitement, as it's expected to eliminate the burdensome 280E tax, unlock institutional investment, and improve banking access for US multi-state operators. While many anticipate substantial gains and 'generational wealth,' some investors are cautiously debating a potential 'sell the news' reaction.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF (DIA) is a central topic as investors await the Federal Reserve's impending rate decision, broadly anticipated as a "hawkish cut," alongside the release of crucial jobs and economic data. Community discussion is split between calls to "buy the dip" and apprehension about a broader market correction, particularly given ongoing weakness in the tech sector, which is fueling talks of a rotation into more established industrial names. This sets the stage for considerable market speculation regarding near-term direction and the potential for year-end gains.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amidst significant community discussion, primarily driven by strong inflows into newly launched XRP ETFs and the anticipation of forthcoming regulatory clarity. While many long-term holders are accumulating during perceived price suppression, attributing it to market manipulation, a vocal segment expresses frustration over the asset's underperformance and its tight correlation to Bitcoin's movements, despite its envisioned utility in global institutional finance.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its passionate community rallies around the concept of "making OG memes great again," emphasizing their consistent building efforts and belief in the project's long-term vision. Discussions highlight the project's unique position as the original "Rage Guy" meme, with calls for a significant market cap target and conviction that strong communities like theirs will drive future crypto growth.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending following its major "System Update" event, which unveiled an ambitious expansion into stock trading, prediction markets powered by Kalshi, and institutional asset tokenization, supported by a new "Buy" rating from Deutsche Bank. This strategic pivot is generating significant community discussion, with some seeing it as a bold move towards becoming an "everything app" on the blockchain, while others view it as a bearish signal for crypto and question its competitive edge against platforms like Robinhood.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Esperion Therapeutics (NASDAQ:ESPR) Sets New 12-Month High - Should You Buy?

Esperion Therapeutics (NASDAQ:ESPR) Hits New 12-Month High - Here's Why...

Two Seas Capital LP Raises Holdings in Esperion Therapeutics, Inc. $ESPR

Two Seas Capital LP raised its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 43.6% in the second quarter, according to the company in its most recent Form 13F...

Esperion Therapeutics (NASDAQ:ESPR) Hits New 52-Week High - Should You Buy?

Esperion Therapeutics (NASDAQ:ESPR) Hits New 1-Year High - Should You Buy...

Esperion Therapeutics (NASDAQ:ESPR) Trading 6% Higher - Here's What Happened

Esperion Therapeutics (NASDAQ:ESPR) Shares Up 6% - What's Next...

Traders Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock traders acquired 4,601 call options on the stock. This...

Esperion Therapeutics (NASDAQ:ESPR) Coverage Initiated at Piper Sandler

Piper Sandler assumed coverage on Esperion Therapeutics in a report on Tuesday. They set an "overweight" rating and a $9.00 target price on the stock...

<ul class="summary-bullets"><li>Piper Sandler projected long-term growth backed by rising use of Esperion’s LDL-lowering therapies and expanding payer coverage.</li><li>Q3 revenue rose sharply as U.S. product sales and collaboration income continued to strengthen.</li><li>The recent Japan launch and milestones from partner Otsuka added to investor optimism about Esperion’s global expansion.</li></ul>Esperion Therapeutics shares climbed to their highest levels in nearly a year on Tuesday after a bullish initiation from Piper Sandler and fresh progress on the company’s international launch plans helped lift investor sentiment.The stock closed 16.4% higher at $3.69 on Tuesday and edged up another 0.3% in after-hours trading, also logging its best session in almost four months.&nbsp;<h2 class="st-heading-2">Piper Sandler Calls Esperion A Strong Risk-Reward Play</h2>Piper Sandler initiated coverage with an ‘Overweight’ rating and projected a potential 144% upside, describing Esperion as a strong risk-reward play supported by accelerating demand for its cholesterol-lowering drug franchise. The firm highlighted the strength of the company’s bempedoic acid–based therapies, Nexletol and Nexlizet, and said it expects continued rapid volume and sales expansion as physicians shift toward non-statin low-density lipoprotein (LDL)-lowering options, according to a report by&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://in.investing.com/news/analyst-ratings/piper-sandler-initiates-esperion-therapeutics-stock-with-overweight-rating-93CH-5124964">Investing</a>.The brokerage pointed to several drivers of long-term growth, including a wide label that covers primary prevention, evolving clinical guidelines that increasingly support the drug class, and broad payer access. A cardiologist-focused survey conducted by the firm reinforced confidence in the therapies’ adoption trajectory.Piper Sandler said it expects Esperion’s products to reach over $650 million in peak U.S. sales, with additional contributions from ex-U.S. royalties, and noted that recent agreements with generic filers provide visibility into exclusivity extending to 2040.Piper Sandler added that Esperion’s risk-reward profile is attractive, noting the stock trades at an enterprise value of roughly 10x estimated 2026 EBITDA, with high visibility into a long-term EBITDA compound annual growth rate above 30% from 2026 through 2031. This long-term view remains intact even as the company reported an EBITDA loss of $29.27 million over the last twelve months.<h2 class="st-heading-2">Esperion Posts Strong Q3 Growth</h2>Esperion reported third-quarter (Q3) total revenue of $87.3 million, an increase of 69% year-on-year, with U.S. net product revenue rising 31% year-on-year to $40.7 million. Collaboration revenue strengthened as well, supported by higher royalty sales and product supply to partners. The company reported an EBITDA loss of $29.27 million, net loss of $31.3 million, and ended the quarter with $92.4 million in cash and cash equivalents. U.S. commercial coverage expanded to more than 90% of commercial lives and over 80% of Medicare beneficiaries, and total prescription volume increased during the period.<h2 class="st-heading-2">Japan Launch Builds Global Momentum</h2>Esperion’s upward momentum comes shortly after a major international milestone. Last week, the company said that its partner Otsuka Pharmaceutical received National Health Insurance Price Listing in Japan and launched Nexletol for hypercholesterolemia and familial hypercholesterolemia. Japan represents the third largest global market for cardiovascular prevention, marking a significant expansion opportunity for Esperion’s cholesterol franchise.Under the agreement, Esperion will receive a $90 million payment tied to Otsuka’s recent regulatory and pricing achievements. The company is also eligible for additional sales milestone payments and tiered royalties of 15% to 30% on net sales in Japan.<h2 class="st-heading-2">Stocktwits Traders Signal Long-Term Confidence</h2>On Stocktwits, retail sentiment for Esperion was ‘extremely bullish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:972/146;" src="https://news.stocktwits-cdn.com/espr_stock_png_0574a99904.webp" alt="espr stock.png" width="972" height="146"><figcaption>ESPR sentiment and message volume as of November 25 | Source: Stocktwits</figcaption></figure>One user said they did not see a buyout happening soon, noting that Esperion already has a growing commercial drug, additional pipeline assets and a path toward profitability.<stembedurl>https://stocktwits.com/Petey3163/message/637466961</stembedurl>Another user said they expected to remain invested for 18 to 24 months, describing cardiovascular opportunities as early and ESP-2001 as still upcoming, and added that they had built a large position and planned to hold.<stembedurl>https://stocktwits.com/Lskynrd1/message/637466633</stembedurl><a href="https://stocktwits.com/symbol/ESPR">Esperion Therapeutics’ stock</a> has risen 67% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Esperion Therapeutics Inc. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug 

Piper Sandler projected long-term growth backed by rising use of Esperion’s LDL-lowering therapies and expanding payer coverage.

Equity

Esperion Therapeutics (NASDAQ:ESPR) Trading Up 4.1% - Should You Buy?

Esperion Therapeutics (NASDAQ:ESPR) Shares Up 4.1% - Still a Buy...

Esperion Partner HLS Receives Health Canada Approval For NILEMDO To Lower LDL-Cholesterol

(RTTNews) - Esperion Therapeutics, Inc. (ESPR) on Tuesday said HLS Therapeutics Inc. (HLS), its partner in Canada for NILEMDO, has received Health Canada approval to market NILEMDO for reducing...

HC Wainwright Has Positive Outlook for ESPR FY2025 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - HC Wainwright increased their FY2025 earnings estimates for shares of Esperion Therapeutics in a note issued to investors on Thursday...

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Esperion Therapeutics Inc.

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.29	--	--	N/A
Q3 '25	-$0.08	-$0.16	-104.27%	MISSED
Q2 '25	-$0.15	-$0.02	86.27%	BEAT
Q1 '25	-$0.15	-$0.21	-35.69%	MISSED
Q4 '24	-$0.13	-$0.11	16.70%	BEAT

ESPR
Esperion Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ESPR News

ESPREsperion Therapeutics Inc.